Bevacizumab and rapamycin reduces central corneal haze

Article

Bevacizumab and rapamycin reduces central corneal haze and apoptotic keratocyte number after photorefractive keratectomy (PRK).

Bevacizumab and rapamycin reduces central corneal haze and apoptotic keratocyte number after photorefractive keratectomy (PRK).

Dr Jae Yong Kim et al., Department of Ophthalmology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, studied a total of 60 right eyes of Sprague-Dawley rats separated into four groups of 15 eyes. The groups included eyes soaked with 0.02% mitomycin C (MMC), eyes administered 2.5% bevacizumab, eyes that received 0.01% rapamycin and a control group.

Each rat underwent PRK ablation to 80 μm with a 3-mm zone. All right eyes were exposed to 100 mJ/cm2 UV-B irradiation at three weeks postoperatively. The amount of haze was determined by biomicroscopy and TUNEL staining was used for apoptosis. Histology was also performed at three, six and twelve weeks.

At three weeks after PRK, central corneal haze, apoptotic keratocyte and keratocyte number significantly decreased in the MMC, bevacizumab and rapamycin groups, compared to the control group.

Keratocyte number was lower in the MMC group compared to the bevacizumab and rapamycin groups at six weeks. Apoptotic keratocyte number was lower in the MMC, bevacizumab and rapamycin groups at twelve weeks, compared to the control group.

Bevacizumab and rapamycin could be safe alternatives to MMC during refractive surgery, in order to prevent postoperative corneal opacity.

The study can be found in the latest online issue of Investigative Ophthalmology and Visual Science.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
© 2025 MJH Life Sciences

All rights reserved.